Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 12;8(10):282.
doi: 10.3390/v8100282.

The Immune Response in Measles: Virus Control, Clearance and Protective Immunity

Diane E Griffin  1
Affiliations
Review

The Immune Response in Measles: Virus Control, Clearance and Protective Immunity

Diane E Griffin. Viruses. .

Abstract

Measles is an acute systemic viral infection with immune system interactions that play essential roles in multiple stages of infection and disease. Measles virus (MeV) infection does not induce type 1 interferons, but leads to production of cytokines and chemokines associated with nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) signaling and activation of the NACHT, LRR and PYD domains-containing protein (NLRP3) inflammasome. This restricted response allows extensive virus replication and spread during a clinically silent latent period of 10-14 days. The first appearance of the disease is a 2-3 day prodrome of fever, runny nose, cough, and conjunctivitis that is followed by a characteristic maculopapular rash that spreads from the face and trunk to the extremities. The rash is a manifestation of the MeV-specific type 1 CD4⁺ and CD8⁺ T cell adaptive immune response with lymphocyte infiltration into tissue sites of MeV replication and coincides with clearance of infectious virus. However, clearance of viral RNA from blood and tissues occurs over weeks to months after resolution of the rash and is associated with a period of immunosuppression. However, during viral RNA clearance, MeV-specific antibody also matures in type and avidity and T cell functions evolve from type 1 to type 2 and 17 responses that promote B cell development. Recovery is associated with sustained levels of neutralizing antibody and life-long protective immunity.

Keywords: antibody maturation; inflammasome; rash; viral RNA persistence.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic diagram of measles virus (MeV) clearance and immune responses in rhesus macaques. Infection with wild type (WT) MeV results in viremia (infectious virus) and rash. The rash is associated with appearance of interferon (IFN)-γ-producing T cells that decline quickly after the viremia is cleared. There is a prolonged phase of slow viral RNA clearance from peripheral blood mononuclear cells (PBMCs) with persistence of viral RNA in lymph nodes (LN). During RNA clearance antibody increases in amount and avidity. Waves of MeV-specific T cells continue to appear in circulation with a shift from IFN-γ production to interleukin 17 (IL-17) production. Data graphed from Lin et al. [9,20].
Figure 2
Figure 2
Time course for production of MeV-specific immunoglobulin G (IgG) and maturation of antibody avidity after infection. (A) Binding IgG antibody to MeV as determined by enzyme immunoassay; (B) Avidity of the antibody from panel A as measured by ammonium thiocyanate elution. Red boxes indicate the period of the rash. Data graphed from Pan et al. [65].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Moss W.J., Griffin D.E. Measles. Lancet. 2012;379:153–164. doi: 10.1016/S0140-6736(10)62352-5. - DOI - PubMed
    1. Wolfson L.J., Grais R.F., Luquero F.J., Birmingham M.E., Strebel P.M. Estimates of measles case fatality ratios: A comprehensive review of community-based studies. Int. J. Epidemiol. 2009;38:192–205. doi: 10.1093/ije/dyn224. - DOI - PubMed
    1. Nandy R., Handzel T., Zaneidou M., Biey J., Coddy R.Z., Perry R., Strebel P., Cairns L. Case-fatality rate during a measles outbreak in eastern Niger in 2003. Clin. Infect. Dis. 2006;42:322–328. doi: 10.1086/499240. - DOI - PubMed
    1. Shibeshi M.E., Masresha B.G., Smit S.B., Biellik R.J., Nicholson J.L., Muitherero C., Shivute N., Walker O., Reggis K., Goodson J.L. Measles resurgence in southern Africa: Challenges to measles elimination. Vaccine. 2014;32:1798–1807. doi: 10.1016/j.vaccine.2014.01.089. - DOI - PubMed
    1. Centers for Disease CaP Increased transmission and outbreaks of measles—European region, 2011. MMWR. 2012;60:1605–1610. - PubMed

Publication types